MAIA Biotechnology, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. MAIA is a clinical-stage oncology biotechnology company with no product revenue; its lead candidate, THIO, is being evaluated in the THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). Financial statements are unaudited.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.32 million | $2.20 million |
| General and administrative expense | $1.63 million | $1.99 million |
| Total operating expenses / operating loss | $3.95 million | $4.18 million |
| Net loss | $8.07 million | $4.12 million |
| Net loss per share, basic and diluted | $0.46 | $0.38 |
| Net cash used in operating activities | $3.59 million | $3.36 million |
| Cash at period end | $8.27 million | $7.15 million at Dec. 31, 2023 |
| Working capital | $3.79 million | Increased about $1.17 million from Dec. 31, 2023 |
- There is no meaningful revenue or gross-margin measure because the company has not generated revenue.
- Operating expenses fell 6% year over year: R&D rose 6%, mainly from higher scientific and clinical research costs, while G&A fell 18%, reflecting lower investor-relations, payroll, and professional-fee costs.
- Net loss nearly doubled, primarily because a $4.18 million noncash loss from remeasuring warrant liabilities replaced a small gain in Q1 2023. The warrant liability was $9.57 million at March 31, 2024, versus $2.15 million at year-end.
- Financing activities provided $4.72 million, principally from March private placements and ATM share sales; cash increased by $1.12 million during the quarter. No conventional borrowings are reported on the balance sheet; current liabilities were $4.91 million.
- Stockholders’ equity was a deficit of $5.76 million at March 31, 2024, versus equity of $0.48 million at year-end. Common shares outstanding increased from 16.99 million to 20.58 million during the quarter.
Business developments, outlook, and risks
- Management reported that THIO-101 completed enrollment at the selected 180 mg dose, reaching 41 patients at that dose. The company also described preliminary results, including a 38% overall response rate in an efficacy-evaluable third-line subgroup and an 85% disease control rate across third-line patients in a March 2024 data cut. These are company-reported interim clinical observations, not established efficacy conclusions.
- Management plans further development of THIO, including potential studies in other cancer indications, but the filing gives no financial guidance or quantified operating outlook.
- The company has recurring losses, negative operating cash flow, and an accumulated deficit of $72.05 million. Management states that additional equity or debt financing will be needed and that substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the statements. Expense-control plans do not eliminate that uncertainty.
- After quarter-end, the company reported additional ATM sales and an April private placement. As of the report date, cumulative ATM gross proceeds were approximately $3.01 million; April private-placement gross proceeds were approximately $1.0 million. These financings provide capital but increase potential dilution.
- In May 2024, the company amended certain warrants to facilitate equity classification in future periods. Warrants issued in financings are a significant source of noncash fair-value volatility and potential dilution.
- The filing identifies risks including dependence on future financing, clinical and regulatory uncertainty, reliance on third parties, and possible loss of NYSE American listing compliance. The company reported it was then compliant under alternate listing standards despite its stockholders’ deficit. It also says planned research activities in areas affected by the wars in Ukraine and Israel were terminated.
- Management concluded disclosure controls were effective at the reasonable-assurance level. The company reported no material legal proceedings and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Current cash runway, expected quarterly cash burn, and whether additional financing will be required on acceptable terms.
- THIO-101 enrollment, follow-up duration, data maturity, safety, and the methods and patient populations behind interim efficacy statistics.
- Potential dilution from outstanding warrants and options, future ATM sales, and private placements; reconcile share counts and warrant terms.
- How warrant amendments affect classification and future reported earnings, and whether remaining warrant fair-value changes could materially affect results.
- Continued compliance with NYSE American listing requirements and progress toward clinical, regulatory, and financing milestones.